Precigen, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74017N1054
USD
3.75
0.27 (7.76%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.91 M

Shareholding (Mar 2025)

FII

0.92%

Held by 43 FIIs

DII

90.84%

Held by 17 DIIs

Promoter

0.09%

How big is Precigen, Inc.?

22-Jun-2025

As of Jun 18, Precigen, Inc. has a market capitalization of 427.89 million, with net sales of 4.20 million and a net profit of -156.65 million over the latest four quarters. Shareholder's funds are 66.73 million, and total assets amount to 146.54 million.

As of Jun 18, Precigen, Inc. has a market capitalization of 427.89 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 4.20 million, while the sum of net profit for the same period is -156.65 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 66.73 million and total assets of 146.54 million.

Read More

What does Precigen, Inc. do?

22-Jun-2025

Precigen, Inc. is a biotechnology company focused on developing biologically-based products using synthetic biology, with a market cap of approximately $427.89 million. As of March 2025, it reported net sales of $1 million and a net loss of $54 million.

Overview: <BR>Precigen, Inc. is a biotechnology company that collaborates to create biologically-based products and processes using synthetic biology, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -54 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 427.89 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -5.13 <BR>Return on Equity: -542.41% <BR>Price to Book: 27.68<BR><BR>Contact Details: <BR>Address: 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD: 20876 <BR>Tel: 1 301 5569900 <BR>Website: https://www.dna.com/

Read More

Should I buy, sell or hold Precigen, Inc.?

22-Jun-2025

Who are in the management team of Precigen, Inc.?

22-Jun-2025

As of March 2022, the management team of Precigen, Inc. includes Executive Chairman Randal Kirk, Lead Independent Director Robert Shapiro, and Independent Directors Cesar Alvarez, Steven Frank, Vinita Gupta, and Fred Hassan. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Precigen, Inc. includes the following individuals:<BR><BR>- Mr. Randal Kirk, who serves as the Executive Chairman of the Board.<BR>- Mr. Robert Shapiro, who is the Lead Independent Director.<BR>- Mr. Cesar Alvarez, an Independent Director.<BR>- Mr. Steven Frank, also an Independent Director.<BR>- Ms. Vinita Gupta, another Independent Director.<BR>- Mr. Fred Hassan, who is an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Read More

Is Precigen, Inc. technically bullish or bearish?

20-Sep-2025

As of July 7, 2025, Precigen, Inc. shows a bullish technical trend despite some short-term weakness indicated by the weekly RSI, having outperformed the S&P 500 significantly with a year-to-date return of 239.29% compared to 12.22%.

As of 7 July 2025, the technical trend for Precigen, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish, supported by weekly and monthly MACD readings, which are both bullish, and daily moving averages indicating bullish momentum. However, the weekly RSI is bearish, which suggests some short-term weakness. The Bollinger Bands are bullish on a weekly basis and mildly bullish monthly, while the KST is bullish in both timeframes. Dow Theory presents a mixed view with a mildly bearish weekly stance but a mildly bullish monthly outlook. <BR><BR>In terms of performance, Precigen has significantly outperformed the S&P 500 year-to-date with a return of 239.29% compared to the S&P 500's 12.22%, and over the past year, it has returned 265.38% versus the benchmark's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of -46.64% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -40.83
2

Negative results in Jun 25

3

Risky - Negative EBITDA

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,265 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

9.98

stock-summary
Return on Equity

1,472.07%

stock-summary
Price to Book

-214.58

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-27 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-21.05%
0%
-21.05%
6 Months
175.74%
0%
175.74%
1 Year
334.13%
0%
334.13%
2 Years
215.13%
0%
215.13%
3 Years
98.41%
0%
98.41%
4 Years
2.18%
0%
2.18%
5 Years
-55.75%
0%
-55.75%

Precigen, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-46.64%
EBIT Growth (5y)
5.71%
EBIT to Interest (avg)
-40.83
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-5.13
Sales to Capital Employed (avg)
0.00
Tax Ratio
1.14%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
30.61%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
29.24
EV to EBIT
-4.01
EV to EBITDA
-4.17
EV to Capital Employed
-5.84
EV to Sales
88.71
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-542.41%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 35 Schemes (8.15%)

Foreign Institutions

Held by 43 Foreign Institutions (0.92%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -30.77% vs 8.33% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 50.92% vs -175.13% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.90",
          "val2": "1.30",
          "chgp": "-30.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.20",
          "val2": "-22.00",
          "chgp": "-23.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.60",
          "val2": "-32.50",
          "chgp": "101.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.60",
          "val2": "-54.20",
          "chgp": "50.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-32,543.20%",
          "val2": "-16,850.10%",
          "chgp": "-1,569.31%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -37.10% vs -76.95% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -31.60% vs -20.18% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.90",
          "val2": "6.20",
          "chgp": "-37.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-90.20",
          "val2": "-82.30",
          "chgp": "-9.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.50",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-40.30",
          "val2": "-10.80",
          "chgp": "-273.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-126.20",
          "val2": "-95.90",
          "chgp": "-31.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-24,128.70%",
          "val2": "-14,284.80%",
          "chgp": "-984.39%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.90
1.30
-30.77%
Operating Profit (PBDIT) excl Other Income
-27.20
-22.00
-23.64%
Interest
0.00
0.00
Exceptional Items
0.60
-32.50
101.85%
Consolidate Net Profit
-26.60
-54.20
50.92%
Operating Profit Margin (Excl OI)
-32,543.20%
-16,850.10%
-1,569.31%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -30.77% vs 8.33% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 50.92% vs -175.13% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
3.90
6.20
-37.10%
Operating Profit (PBDIT) excl Other Income
-90.20
-82.30
-9.60%
Interest
0.00
0.50
-100.00%
Exceptional Items
-40.30
-10.80
-273.15%
Consolidate Net Profit
-126.20
-95.90
-31.60%
Operating Profit Margin (Excl OI)
-24,128.70%
-14,284.80%
-984.39%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -37.10% vs -76.95% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -31.60% vs -20.18% in Dec 2023

stock-summaryCompany CV
About Precigen, Inc. stock-summary
stock-summary
Precigen, Inc.
Pharmaceuticals & Biotechnology
Precigen, Inc., formerly Intrexon Corporation, forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.
Company Coordinates stock-summary
Company Details
20374 SENECA MEADOWS PARKWAY , GERMANTOWN MD : 20876
stock-summary
Tel: 1 301 5569900
stock-summary
Registrar Details